Free Newsletter
Diabetes drugs linked to fracture risk
One more strike against diabetes drugs. Australia's regulators are warning that the class of drugs including Avandia and Actos may boost the risk of bone fractures in older women.
A four-year study of 4,360 patients showed that post-menopausal women taking one of the thiazolidinediones were more likely to break a bone. The Therapeutic Goods Administration won't withdraw the drugs, but manufacturers are warning doctors about the newly identified risks.
- read the report from the Sydney Morning Herald
Related Articles:
Avandia, Actos don't boost death risk. Report
Actos on a good-news roll. Report
Avandia risks back in the headlines. Report
Australia bans Novartis' Prexige. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: